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N the spring of 2007, a 2-year clinical drug trial began at Children's Hospital Boston (I) with the goal to advance the quality of life for children with Hutchinson-Gilford progeria syndrome (henceforth progeria), a rare (frequency I in 4 million), multisystem, and inevitably l~llal disease that claims young lives due to myocardial infarctions and strokes between ages 7 and 20 years (2) . The journey to the first clinical trial for progeria has been facilitated by a series of collaborative scientific workshops organized by The Progeria Research Foundation (PRF) and supp0l1ed by agencies interested in aging, cardiovascular disease, rare disease research, and genetics (http://www.progeriaresearch. org/2007_prl"-workshop_on_progeria.html). These meet ings have provided a concentrated forum to facilitate the collective thinking of clinicians and scientists about progeria, forge collaborations in this little-known field, and accelerate the discovery of new ways to push the field forward toward treatments and cure. The first PRF Scientific Workshop in 2001 helped to identify nuclear blebbing as an imp0l1ant phenotypic marker of progeria cells (noted by Anthony Weiss; University of Sydney, Australia), and to recognize a translocation on chromosome 1 in the cells cultured from a progeria patient (W. Ted Brown, New York State Institute for Basic Research in Developmental Dis abilities), pointing geneticists in the direction of the gene mutation for progeria (3) . In 2003, the second workshop was held just 3 months after publication of the gene defect in progeria, which is typically a sporadic autosomal domi nant disease caused by a C --, T mutation at nucleotide 1824 of the LMNA gene encoding lamin A (4, 5) . Importanlly, the mutation results in a persistence of an aberrant form of a famesylated-prelamin A molecule (4) now called progerin. The attendees now included expelts in the field of lamin biology and laminopathies. The 2004 Progeria Workshop, held within the National Human Genome Research Institute (NHGRI), was held specifically to discuss the role of stem cells and the potential for stern cell transplantation in progeria, an area of continuing interest for the field. At the general Progeria Workshop in 2005, two mouse models of progeria were unveiled and, although they contained iden tical mutations, they yielded very different phenotypes, mimicking various pOltions of the human disease (6,7).
Early in vitro data on a potential role of famesy!transferase inhibitors (FTIs) in treating progeria were presented by four laboratories, demonstrating that FTl could reverse nuclear blebbing in cells expressing progerin (8-11). Armed with data demonstrating that treatment of newly developed cellular assays with FTIs improves or reverses some of the effects of progerin accumulation, a clinical trial treating children with progeria with an FTI was initiated in May 2007 (I) (www.c1inicaltrials.gov ).
The present article, detailing the 2007 PRF Scientifk Workshop (November 12-14, Boston), emphasizes the complexities of progerin and lamin A biology, and the need to continue 10 look for the most effective protocols for correcting the effects of the lamin A defect in progeria. All speakers presented preliminary data that had not been peer reviewed at the lime of presentation. In the months since the workshop, some data have been published (referenced within this article), and we look forward to additional peer reviewed publications on the work presented at this meeting over the coming year.
The essence of translational research was represented in the presentations, which brought forth the most impOltant issues in progeria today-the effects of progerin and lamins and their binding partners on the functioning of cells, sys tems, mouse models, and humans; the connection between progeria, aging, and cardiovascular disease in the general population; careful analysis of ITI effects on progeria at all levels (summarized in Table 1) ; and strategies for future disease treatments and cure. In his introduction at the work shop, Francis Collins (Director, NHGRI) noted that a 4-year period between gene discovery and a clinical drug trial is
. an unprecedentedfeatfor a rare genetic disease." For progeria patients and their families, who have struggled to live within a void of infonnation, the clinical trial represents ... a source of light coming up after a long, long night" and hope has replaced" ... a sense of fear and helplessness on each passing birthday" (Subbarao, father of Priya, a 15 year-old with progeria).
GETTING TO KNOW THE CHILD WITH PROGERIA
For a disease as rare as progeria, scientists often have no exposure to the very population they wish to serve. During
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The attendees now included expelts in the field of lamin biology and laminopathies. The 2004 Progeria Workshop, held within the National Human Genome Research Institute (NHGRI), was held specifically to discuss the role of stem cells and the potential for stem cell transplantation in progeria, an area of continuing interest ror the field. At the general Progeria Workshop in 2005, two mouse models of progeria were unveiled and, although they contained iden tical mutations, they yielded very different phenotypes, mimicking various p0l1ions of the human disease (6,7).
Early in vitro data on a potcntial role of famesyltransferase inhibitors (FTls) in treating progeria were presented by four laboratories, demonstrating that FTI could reverse nuclear blebbing in cells expressing progeri n (8-1 I). Armed with data demonstrating that treatment of newly developed cellular assays with FTls improves or reverses some of the errects of progerin accumulation, a clinical trial treating children with progeria with an FTl was initiated in May 2007 (I) (www.c1inicaltrials.gov).
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Workshop (November 12-14, Boston), emphasizes the complexities of progerin and lamin A biology, and the need to continue to look for the most effective protocols ror correcting the effects of the lamin A defect in progeria. All speakers presented preliminary data that had not been peer reviewed al the time of presentation. In the months since the workshop, some data have been published (referenced within this article), and we look forward to additional peer reviewed publications on the work presented at this meeting over the coming year.
The essence of translational research was represented in the presentations, which brought forth the most impOltant issues in progeria today-the efrects or progerin and lamins and their binding partners on the functioning of cells, sys tems, mouse models, anel humans; the connection between progeria. aging, and cardiovascular disease in the general population; careful analysis of FTI effects on progeria at all levels (summarized in Table 1 ); and strategies for future disease treatments and cure. In his introduction at the work shop, Francis Collins (Director, NHGRI) noted that a 4-year period between gene discovery and a clinical drug trial is " " ... an IlJlprecedented./£>a1/or a rare genetic disease." For progeria patients and their families, who have struggled to live within a void of infonnation, the clinical trial represents " " ... a source of light coming up after a long, long nighl" and hope has replaced" ... a sense of fear and helplessness on each passing birthday" (Subbarao, (-~Ither of Priya, a 15 year-old with progeria).
GETTING TO KNOW THE eHlU) WITH PROGERIA For a disease as rare as progeria, scientists often have no exposure to the very population they wish to serve. During the first evening of the workshop, participants had a unique chance to hear from children with progeria and their families during a panel discussion. Dr. Scoff Berns (PRF and Warren Alpert Medical School of Brown University), the father of a child with progeria, moderated the family session. Through intellJrcters, Sammy (12 year old from Italy) and Priya (15 year old from India), displayed an uncanny ability to describe their lives with eloquence, poise, and wisdomt heir frail and aged physical appearance belying their lively spirits. Priya shared that she enjoys traveling, and Sammy liked to skateboard, swim, and is well assimilated into school life. Sammy's parents, Laura and Amerigo, spoke about how their son" ...gives them the strength to keep on and to not give up, and always look at the good side of the day." Sammy has given them an ...opportunity to enjoy life in a different way ....to enjoy every day of your life with your child Keith and Molly Moore (U.S.A.), parents or Zachary, who recently passed away, described the selfless traits of their son as well as other children with progeria, relating how children with progeria ...care so much for others, and Zach understood that the research might not help him directly and personally, but it certainly would help others" (12) . In concluding, young Sammy wanted to especially ...thank all the doctors and all the researchers that are putting such an effort into trying to help me out and all the other kids with the disease."
DESIGNING THE FIRST CLINICAL DRUG TRIAL
The ultimate goals of disease-related research are to find treatments and a cure~il1 this case to improve the health and increase the life spans of children with progeria. Designing a clinical trial that has the greatest chance of assessing the efficacy of an intervention on the disease in a statistically signillcant manner is a key element in this process. For a disease such as progeria, in which fewer than 50 patients are identified worldwide at anyone time, this is especially challenging. To that end, a clinical trial using FTI to treat progeria is currently being conducted at Children's Hospital, Boston. Several of the trial team members presented baseline clinical studies or the major systems affected in progeria, trial design, and measures of efficacy that will likely serve as models for future treatment trials in Ihe field.
Mark Kieran (Dana Farber Cancer Institute), principal investigator of the clinical trial team, reviewed the rationale for the clinical trial design, drug selection, and parameters for assessing drug efficacy. The selection of the FTI lonaramib was made on the basis of two lines of evidence: the addition of FTI to progeria l1broblasls reverses nuclear blebbing (8-11), and its low toxicity profile in adults and children with cancer (13) . However, because 10nafamib has not previously been administered to children with progeria, it will be impOltant to carefully track the toxicity profile, pharmacokinetics, and efficacy or lonafarnib in a variety of organ systems to dete1111ine whether there is any benefit to using this FTI in progeria clinically. To quantitate the effect of drug treatment in a measurable way, Dr. Kieran stressed the importance of first documenting the natural history of the disease, including an understanding of the breadth and variability in disease phenotype from patient to patient. Because the number of children with progeria is often too small to see population-based changes, for some clinical measures each child must serve as his or her own control for assessing drug efrect, comparing pretreatment measures to posttreatment measures. Because disease in progeria is progressive, any measures improving with treatment would be considered drug-related changes. The primary clinical parameter for measuring treatment effkacy is rate of weight gain, which is linear for each child after approximately age 2 years in progeria (14) , and therefore provides an opportunity to assess whether FTI affects rate of weight gain over a 2 year treatment period. Secondary parameters of efficacy 778 GORDON ET AI.,. the first evening of the workshop, participants had a unique chance to hear li"OITI children with progeria and their families during a panel discussion. Dr. Scotf Berns (PRF and Warren Alpert Medical School of Brown University), lhe father of a child with progeria, moderated the family session. Through inlellJreters, Sammy (12 year old from Italy) and Priya (15 year old ti"om India), displayed an uncanny ability to describe their lives with eloquence, poise, and wisclom their frail and aged physical appearance belying their lively spirits. Priya shared that she enjoys traveling, and Sammy liked to skateboard, swim, and is well assimilated into school life. Sammy's parents, Laura and Amerigo, spoke about how their son" ...gives them the strength to keep on and to not give up, and always look at the good side or the day." Sammy has given them an " "." .opportunity to enjoy life in a different way ....to enjoy every day of your life with your child ... ". Keith and Molly Moore (U.S.A.), parents of Zachary, who recently passed away, described the selfless traits of their son as well as other children with progeria, relating how children with progeria " " ...care so much for others, and Zach understood that the research might not help him directly and personally, but it certainly would help others'· (12). In concluding, young Sammy wanted to especially "" ...thank all the doctors and all the researchers that are putting such an effort into trying to help me out and all the other kids with the disease."
The ultimate goals of disease-related research are to find treatments and a cure-in this case to improve the health and increase the life spans of children with progeria. Designing a clinical trial that has the greatest chance of assessing the efficacy of an intervention on the disease in a statistically significant manner is a key element in this process. For a disease such as progeria, in which fewer than 50 patients are identified worldwide at anyone time, this is especially challenging. To that end, a clinical trial using FTI to treal progeria is currently being conducted at Children '."I Hospital, Boston. Several of the trial team members presented baseline clinical studies of the major systems affected in progeria, trial design. and measures of efficacy that will likely serve as models for future treatment trials in the field. (Dana Farber Cancer Institute) , principal investigator of the clinical trial team, reviewed the rationale for the clinical trial design. drug selection, and parameters for assessing drug efficacy. The selection of the FTf lonafamib was made on the basis of two lines of evidence: the addition of FTI to progeria l1broblasls reverses nuclear blebbing (8-11), and its low toxicity profile in adults and children with cancer (13) . However, because lonafamib has not previously been administered to children with progeria, it will be imp0l1ant to carefully track the toxicity profile, pharmacokinetics, and efficacy or lonafarnib in a variety of organ systems to detem1ine whether there is any benefit to lIsing this FTI in progeria clinically. To quantitate the effect of drug treatment in a measurable way, Dr. Kieran stressed the importance of first documenting the natural history of the disease, including an understanding of the breadth and variability in disease phenotype from patient to patient. Because the number of children with progeria is often too small to see population-based changes. for some clinical measures each child must serve as his or her own control for assessing drug effect, comparing pretreatment measures to posUreatment measures. Because disease in progeria is progressive, any measures improving with treatment would be considered drug-related changes. The primary clinical parameter for measuring treatment eflkacy is rate of weight gain, which is linear for each child after approximately age 2 years in progeria (J 4). and therefore provides an opportunity to assess whether FrI affects rate of weight gain over a 2 year treatment period. Secondary parameters of efficacy include measures of abnormality in other well-known features of the disease, such as alopecia, short slature, subcutaneous !~lt. bone integrity, limb abnormalities. auditory and dental abnonnalities, and cardiovascular disease. While these features arc important to the disease process, the ability to statistically assess lrealmenl effect on these systems is Jess reliable than rate of weight gain. Although cardiovascular disease is clinically the most important determinant of health and longevity in progeria, it is currently not a feasible primary outcome measure for a clinical triaL but is followed as a secondary measure. Some patients in the study have already hacl myocardial infarctions or strokes, and the damage incurred cannot predictably be reversed. In addition, the ages for participants in the trial range from 3 to 16 years. Because the most accurate assessment of cardiovascular improvement would be an increase in mean age of death, the clinical trial with a cardiovascular primal)' parameter would require a 10-to IS-year commitment. Hence, rate of weight gain is used as a surrogate marker of general health in progeria.
Mark Kieran
In addition to rate of weight gain, other more focused features such as bone heallh could change in a measurable way within the 2-year treatment period. Catherine Gordon (Children's Hospital, Boston) presented the preliminary data on the bone phenotype for 28 children, measured using two dimensional dual-energy x-ray absorptiometry. Because the body habitus of children with progeria is drastically different from their age-matched peers, calculation adjust ments must be made for height-age. Remarkably, the clinical histories indicate that children with progeria do not have a higher risk of fracturing their weight-bearing bones, although they are very playful and active. She suspects that fracture rates in progeria children are not increased because the cortex of weight-bearing long bones is of nOl1nal density by x-ray (14) , in contrast to other low weight-disorders such as anorexia nervosa and cystic fibrosis, where fracture rates are increased and cortical bone is thinned on x-ray. In support of this hypothesis, pre liminary data demonstrated that bone density z-scores move from an uncorrected osteoporotic range of -2 to -4, where we would expect some spontaneous bone breaks similar to osteogenesis imperf'ecta, to a height-age cOlTected osteo penic range of' -1 to --2. Further studies of bone quality are in progress, using peripheral qualllitative computed tomog raphy to track the three-dimensional cortical and trabecular characteristics with and without FTI treatment THE CARDIOVASClJLAR PHENOTYPE IN PROGEIHA AND PROSIJECTS FOR VASClJl,AR TlmATMENT WITH FTI Cardiovascular events in progeria include hypertension, myocardial infarction, congestive heart failure, and stroke. Elizabeth Nobel (National Heart. Lung and Blood Institute) and Marie Gerhard-Herman (Brigham and Women's Hospital) discussed recent findings on the vascular pheno type and function in children with progeria. It was the consensus of both presenting clinicians that the disease progression of progeria blood vessels does not lit the typical atherosclerotic description that includes: a) preservation or the vascular smooth muscle cells (VSMC), b) intimal thickening, c) atherosclerotic plaque (rich lipid core) with ruptured cap and superimposed thrombosis, and d) some proliferating smooth muscle cells. Instead, Drs. Nabel and Gerhard-Herman propose that progeria vascular phenotype resembles an arteriosclerosis, which is characterized by hardening of the vessels and vascular stiffness, typically seen in the nOl1nal aging populations. Vessel cross-sections at autopsy or one 20-year-old patient revealed no indication of vasculature inHammation (IS). In addition, children with progeria do not have abnormal serum cholesterol levels, which is a factor in chronic lipid-driven int-lammation (16) . Clinical studies at both the National Institutes or Health (NIH) clinical center (17) and Children's Hospital, Boston, revealed that the intima-media thickness of the progeria carotid artery is normal. Furthennore, in agreement with Stehbens and colleagues (I5), Dr. Nabel presented autopsy cross-sections from a child with genetically confinned progeria, and the histology showed that the v,lscular media no longer contained smooth muscle cells and the elastic structure was destroyed and replaced with extracellular matrix or fibrosis. She hypothesized that the primary loss of smooth muscle cells initiates vascular remodeling by secondary replacement with matrix in large and small vasculature.
In a study of 28 children with progeria at Brigham and Women's Hospital (Boston), Dr. Gerhard-Hennan measured global vascular stiffening and, through imaging techniques, observed vessel tortuosity, profound adventitial thickening, and a depleted media layer. For children with an occluded internal carotid artery, there was an overall loss of the trilaminar architecture. Functional studies demonstrated high femoral pulse wave velocities, and decreased vaso dilatory response to nitrous oxide stimulation induced by ankle flexion. Overall, the vessel stiffness, tortuosity, and adventitial brightness (the molecular composition not yet identified), as observed in imaging studies, support a model of arteriosclerosis similar to what is observed in aging. Remarkably, the blood velocities are in the nonnal range and now is still laminar, implying that there is either a tremendous reserve capacity in the vasculature. or there are compensatory mechanisms helping to preserve function. Complementary data gathered at the NIH studying a cohOl1 of 15 patients revealecl initially n01111al vascular compliance that decreases with increasing age, and a number of children displayed len atrial enlargement (17) . Blood pressure and heart rate were in the normal range in younger children, while the older children had increasing blood pressures and variable heart rates. Electrocardiograms were normal in most, although a few had long Q-T intervals suggesting fibrosis of the conduction system. In summary, the progeria vasculature is characterized by global stiffness, tortuosity, and a loss of smooth muscle cells in the media with subsequent extracellular replacement. Smooth muscle cell dropout is unique to progeria, while global stiffness and tortuosity are observed in the nonnal aging population.
The vascular remodeling characteristics in children with progeria are similar to vascular events observed in a trans genic progeria mouse model that expresses human progerin, created in Francis Collins' laboratOl)' (7) . Within the descending aorta (cross-section histology), smooth muscle include measures of abnormality in other well-known features of the disease, such as alopecia, short stature, subcutaneous l~lL bone integrity, limb abnormalities, auditory and dental abnonnalities, and cardiovascular disease. While these features are important to the disease process, the ability to statistically assess treatmenl ellect on these systems is Jess reliable than rate of weight gain. Although cardiovascular disease is clinically the most important determinant of health and longevity in progeria, it is currently not a feasible primary outcome measure for a clinical trial. but is followed as a secondary measure. Some patients in the study have already had myocardial infarctions or strokes, and the damage incurred cannot predictably be reversed. In addition, the ages for participants in the trial range from 3 to 16 years. Because the most accurate assessment of cardiovascular improvement would be an increase in mean age of death. the clinical trial with a cardiovascular primary parameter would require a 10-to IS-year commitment. Hence, rate of weight gain is used as a surrogate marker of general health in progeria.
In addition to rate of weight gain, other more focused features such as bone heallh could change in a measurable way within the 2-year treatment period. Catherine Gordon (Children's Hospital, Boston) presented the preliminary data on the bone phenotype for 28 children, measured using two dimensional dual-energy x-ray absorptiometry. Because the body habit us of children with progeria is drastically different fi'om their age-matched peers, calculation adjust ments must be made for height-age. Remarkably, the clinical histories indicate that children with progeria do not have a higher risk of fracturing their weight-bearing bones, although they are very playful and active. She suspects that fracture rates in progeria children are nol increased because the cortex 01" weight-bearing long bones is of nonnal density by x-ray (14) , in contrast to other low weight-disorders such as anorexia nervosa and cystic fibrosis, where lj'acture rates are increased and cortical bone is thinned on x-ray. ln support or this hypothesis, pre liminary data demonstrated that bone density ;:-scores move from an uncorrected osteoporotic range of -2 to -4, where we would expect some spontaneous bone breaks similar to osteogenesis imperrecta, to a height-age cOITected osteo penic range of -1 to --2. Further studies of bone quality are in progress, using peripheral quantitative computed tomog raphy to track the three-dimensional cortical and trabecular characteristics with and without FTI treatment.
THE CAIWIOVASCLJLAR PHENOTYPE IN PROGEIUA AND PRO,'WECTS FOR VASClJLAR Tnl~ATMI~NT WITH FTI
Cardiovascular events in progeria include hypertension, myocardial infarction, congestive heart failure, and stroke.
E/izab()th Nobel (National Heart. Lung and Blood Institute) and Marie Gerhard-Herman (Brigham and Women's Hospital) discusscd recent findings on the vascular pheno type and function in children with progeria. It was the consensus of both presenting clinicians that the disease progression or progeria blood vessels does not fit the typical atherosclerotic description that includes: a) preservation of the vascular smooth muscle cells (VSMC), b) intimal thickening. c) atherosclerotic plaque (rich lipid core) with ruptured cap and superimposed thrombosis, and d) some proliferating smooth muscle cells. Instead, Drs. Nabel and Gerhard-Herman propose that progeria vascular phenotype resembles an arteriosclerosis, which is characterized by hardening of the vessels and vascular sti llness, typically seen in the nonnal aging populations. Vessel cross-sections at autopsy or one 20-year-old patient revealed no indication of vasculature int-lammation (IS). In addition, children with progeria do not have abnormal serum cholesterol levels, which is a factor in chronic lipid-driven int-lammation (16) , Clinical sludics at both the National Instilutes or Heallh (NII-J) clinical center (17) and Children's Hospital, Boston, revealed that the intima-media thickncss of the progeria carotid artery is normal. Furthennore, in agreement with Stehbens and colleagues (15) . Dr. Nabel presented autopsy cross-sections from a child with genetically confirmed progeria, and the histology showed that the vascular media no longer contained smooth muscle cells and the elastic structure was destroyed and replaced with extracellular matrix or Iibrosis. She hypothesized that the primary loss of smooth muscle cells initiates vascular remodeling by secondary replacement with matrix in large and small vasculature.
In a study of 28 children with progeria at Brigham and Women's Hospital (Boston), Dr. Gerhard-Hennan measured global vascular stiffening and, through imaging techniques, observed vessel lortuosi ty, profound adventitial thicken ing, and a depleted media layer. For children with an occluded internal carotid artery, there was an overall loss of the trilaminar architecture. Functional studies demonstrated high femoral pulse wave velocities, and decreased vaso dilatory response to nitrous oxide stimulation induced by ankle Oexion. Overall, the vessel stiffness, tortuosity, and adventitial brightness (the molecular composition not yel identified), as observed in imaging studies, support a model of arteriosclerosis similar 10 what is observed in aging. Remarkably. the blood velocities are in the nOl1nal range and now is still laminar, implying that there is either a tremendous rescrvc capacity in lhe vasculature. or there are compensatory mechanisms helping to preserve function. Complementary data gathered at the NIH studying a cohOl1 of 15 patients revealed initially n0l111al vascular compliance that decreases with increasing age, and a number of children displayed len atrial enlargement (17) . Blood pressure and heart rate were in the normal range in younger children, while the older children had increasing blood pressures and variable heart rates. Electrocardiograms were normal in most. although a fcw had long Q-T intervals suggesting fibrosis of the conduction system. In summary, the progeria vasculature is characterized by global stiffness, tortuosity, and a loss or smooth muscle cells in the media with subsequent extracellular replacement. Smooth muscle cell dropout is unique to progeria, while global stiffness and tortuosity are observed in the nonnal aging population.
The vascular remodeling characteristics in children with progeria are similar to vascular events observed in a trans genic progeria mouse model that expresses human progerin, created in Francis Collins' laboratory (7) . Within the descending aorta (cross-section histology), smooth muscle To continue developing treatment prospects in progeria, and to understand its role in normal aging, it is essential to study not only the efrects of I',l, bUI also the biology or lamins. progerin, and related molecules at the cellular level. In nOlmal cells, lamins fonn a concentrated layer along the inner rim of the nucleus, called the nuclear lamina, and are also found dispersed within the nucleoplasm (18) . Lamins play a critical role in a number of essential cellular functions, such as the transcription of RNA polymerase It DNA replication, the organization of the chromosome territories, and epigenetic modulations within the nucleus. Lamin A is processed via a series of posttranslational steps ( Figure I ): prelamin A is farnesylated, carboxymethylated, and cleaved twice to produce mature lam in A. Elements for this pathway include initial famesylation by a farnesyltrans ferase, removal of the three C-terminaI amino acids, and methyl esterification of the now C-telminal farnesyl cysteine. This is followed by integration of prelamin A into the nuclear membrane, and cleavage of 15 amino acids and the attached ramesyl group from its C-tenninal end by Zmpste24 to produce mature lamin A. Mature lamin A is then released from the nuclear membrane (19) . Typically in progeria, a single silent C to T transition mutation at nucleotide 1824 (Gly608Gly) activates a cryptic splice site, resulting in the deletion of 150 messenger RNA bases in the 3' portion of exon II (4). The aberrant protein. progerin, lacks the cleavage site for removal of its C-tenninal farnesylated peptide by Zmpste24 endoprotease, and thererore remains bound to the inner nuclear membrane. Hence, progerin resembles an aberrant fom1 of famesylated prelamin A. However, whereas prelamin A is a transient. illlermediate protein, which is present at very low levels in the cell, progerin is a nontransient protein whose concen tration builds with successive cell divisions.
Several workshop presentations addressed progerin's influences on lamin A and its binding pmtners. its role in architectural changes in the nuclear membrane, and sub sequent effects on cell function that include: increase in apoptosis and disruption of binding with lamin-binding proteins; increased nuclear rigidity, sluggish wound healing in vitro, and altered cell proliferation and chromosomal distribution. Ludo Comai's (University of Southern Cal ifornia) studies stressed the importance of detennining the cellular eHects of progerin and excess prelamin A on cell growth (20 To continue developing treatment prospects in progeria, and to understand its role in normal aging, it is essential to study not only the effects of f"J'1, but also the biology of lamins, progerin, and related molecules at the cellular level. In nOlmal cells, larnins Conn a concentrated layer along the inner rim of the nucleus, called the nuclear lamina, and are also found dispersed within the nucleoplasm (18) . Lamins play a critical role in a number of essential cellular functions, such as the transcription of RNA polymerase n.
DNA replication, the organization of the chromosome territories, and epigenetic modulations within the nucleus. Lamin A is processed via a series or posHranslational steps ( Figure I ): prelamin A is farnesylated, carboxymethy lated, and cleaved twice to produce mature lamin A. Elements for this pathway include initial famesylation by a farnesyltrans lerase, removal of the three C-tenninal amino acids, and methyl esterifkation of the now C-telminal farnesyl cysteine. This is followed by integration of prelamin A into the nuclear membrane. and cleavage of 15 amino acids and the attached famesyl group from its C-tenninal end by Zmpste24 to produce mature lamin A. Mature lamin A is then released from the nuclear membrane (19) . Typically in progeria, a single silent C to T transition mutation at nucleotide 1824 (Gly608Gly) activates a cryptic splice site, resulting in the deletion or 150 messenger RNA bases in the 3' portion of exon II (4). The aberrant protein, progerin, lacks the cleavage site for removal of its C-tenninal farnesylated peptide by Zmpsle24 endoprotease, and therefore remains bound to the inner nuclear membrane. Hence, progerill resembles an aberrant fOnll of farnesylated prelamin A. However, whereas prelamin A is a transient intermediate protein, which is present at very low levels in the cell, progerin is a nontransient protein whose concen tration builds with successive cell divisions.
Several workshop presentations addressed progerin's influences on lamin A and its binding paltners. its role in architectural changes in the nuclear membrane, and sub sequent effects on cell function that include: increase in apoptosis and disruption of binding with lamin-binding proteins, increased nuclear rigidity, sluggish wound healing in vitro, and altered cell proliferation and chromosomal distribution. Lucio Comai's (University of Southern Cal ifornia) studies stressed the importance of detennining the cellular effects of progerin and excess prelamin A on cell growth (20) . Dr. Comai used a lentivirus system to create two cell lines, progerin expressors and prclamin A ovcr ex pressors, from normal human fibroblasts. Over-expression of either prelamin A or progerin significantly increased the amount or cell death compared to wild-type cOlltrols in a passage-independent manner. When progerin-expressing cells 10.' 11 progerill expression, apoplasis decreased to wild-Iype levels. Apoplasis also decreased to wild-Iype levels when prelarnin A overexpressors were transfected with additional Zmpste24 DNA, which decreased prelamin A protein levels and increased mature lamin A levels.
As expected, over-expressing Zmpste24 did no1 rescue progerin-exprcssing cells, because progerin lacks the Zmpsle24 recagni lion site. Adding FII to progerin expressing cell cultures did not improve rates of cell death, presumably because the excess nonfarnesylated prelamin A created with FII exposure counteracted any improvements in growth that decreasing progerin may have caused. Studies by Stephen Young (UCLA) provided additional evidence for the toxic effects of farnesylated prelamin A. Dr. Young showed that certain clinically used HIV protease inhibitors that cause lipodystrophy reminiscent of that seen in progeria also create a Zmpste24 blockade and a build-up of 1~ll11esylated prelamin A in normal fibroblasts (21) . Thus, it is crucial to study not only the effects of progerin, but that of other proteins that are affected by the presence of progerin or by treatments that create an imbalance of lamin A-related proteins.
Jan Lammerding (Harvard Medical School) studied the effects of accumulated progerin on nuclear rigidity, wound healing in vitro, and cell cycling, and asked whether FTls reverse abnormalities. When strain is applied to wild-type fibroblast nuclei, they remain stilT (22) . Fibroblasts cultured from a lamin A/C deficient mouse model were twice as fragile as wild-type cells, and after 24 hours of mechanical strain, cell death signilkantly increased. In sharp contrast, while progeria fibroblasts showed normal rigidity at early passages (when progerin levels and nuclear blebbing are at a minimum), late-passage nuclei show dramatically in creased rigidity over wild-type fibroblasts. Although the lamin A/C defkient fibroblasts and progeria Ilbroblasts displayed vastly different nuclear rigidities, nuclear strain elicited early cell death in both cell types over controls. In addition, whereas wild-type cells elller S phase and G2 phase in response to mechanical stretch, progeria cells did not proliferate in response to stretch. Serum-starved progeria hbroblasts had a slow and incomplete response 10 an in vitro wound healing assay as well. The ability of FTls to affect these cellular abnormalities was mixed. Nuclear rigidity and wound-healing deficits were reversed in PrJ-treated proge ria cultures. However, FTI treutment did not promote cell proliferation after mechanical strain.
Within the nucleus, lamin A monomers first dimcrizc, thcn dirners associate in a head-tn-tail t~lshion and finally associate laterally (23) . The 50-amino acid deletion in progerin probably docs not affect its ability to dimerize, as normal lamin A docs, because the necessary components for this function are not deleted. Hence progcrin can form dimers with itsclf or nOllnal lamin A, thereby inOuencing lamin A's interactions with nuclear pores, chromatin, and lamin binding partners. For example, the fOllllation of larnin A and lamin B are separate yet interdependent; the failure of one lam in-type to properly form can interferc with the formation of another lamin type (24) . Progerin build-up with increasing cell passage leads to progressively increased percentages of blebbed nuclei (25) . Robert Goldman (Northwestern University) referred to these blebs as "sophisticated structures" worthy of close examination to detelllline their inOuence on cell function, and began by hypothesizing that progerin's affect on other lamin types is central to the blebbing defect. In the region of the blebs, there is an absence of heterochromatin but euchromatin can be identified surrounded by lamin A, a configuration not observed in other regions where the nuclear membrane appears to be formed normally (26) . Dr. Goldman and his group suggest that the blebs contain transciptionally active DNA and thut this is providing clues regarding the role of mutant lamin A in progeria.
Complementary chromosome positioning studies were explored by Joanna Bridger (Brunei University, U.K.), who supports the hypothesis that A-type lamins (and/or emerin) are involved in translocating and anchoring chromosomes to the nuclear membrane or nuclear matrix in nonrandom distributions according to cell cycle status, and that lamin mutations pcrturb this balance. Normally, upon cell cycle exit, gene-poor chromosomes move from the nuclear periphery to more interior positions (27, 28) . The distribution profile of chromosome position within the nucleus during cell cycling, quiescence, and senescence all differ. Dr. Bridger had earlier reported that proliferating fibroblasts from laminopathy patients, including progeria, exhibited chromosome distributions characteristic of nonprolifcrating (senescelll or quiescent) n0I111al fibroblasts, where the largest chromosomes are located at the periphery of the nucleus and the smallest at the interior. At the workshop. Dr. Bridger reported new experiments that distinguished the chromosome distribution in senescent from quiescent cells based on the position of chromosome to, which she finds located at the periphery in quiescent cells and at the interior in senescent cells. In proliferating progeria I1broblasts, however, chromosome lO was located at the periphery, a position found only in the nonproliferating, quiescent state in nonnal cells. Several other proliferating laminopathy cultures also displayed the quiescent positioning. This chromosome positioning was not changed when progeria or laminopathy cells became senescent. The consequences of aberrant chromosome 10 locat ion on transcription in progeria will be the subject of Dr. Bridger's future studies.
Bryce Paschal (University of Virginia) reported on progerin-induced changes in the nuclear pore complexes (NPCs), channels through which all transport between the nucleus and the cytoplasm takes pi ace (29) . He has found major changes both in NPC structure and in the transport machinery and signals. The structural change is in the position of the nucleoplasmic basket, a structure located at the pore on the nucleoplasmic side. It consists of two proteins: TPR (translocated promoter region), the key constituent, and Nup 153, a facilitator of its assembly. The entire basket structure is disassemblecl and reassembled at every mitosis. When Dr. Paschal looked for the localization of TPR in progeria fibroblasts by immunostaining, he Jan Lammerding (Harvard Medical School) studied the effects of accumulated progerin on nuclear rigidity, wound healing in vitro, and cell cycling, and asked whether FTls reverse abnormalities. When strain is applied to wild-type fibroblast nuclei, lhey remain stilT (22) . Fibroblasts cultured from a lamin A/C deficient mouse model were twice as fragile as wild-type cells. and after 24 hours of mechanical strain, cell death significantly increased. In sharp conlrast, while progeria fibroblasts showed normal rigidity at early passages (when progerin levels and nuclear blcbbing are al a minimum), late-passage nuclei show dramatically in creased rigidity over wild-type fibroblasts. Although the lamin A/C ddicient fibroblasts and progeria fibroblasts displayed vastly different nuclear rigidities, nuclear strain elicited early cell death in both cell types over controls. In addition, whereas wild-type cells enter S phase and G2 phase in response to mechanical stretch, progeria cells did not proliferate in response to stretch. Serum-starved progeria flbroblasts had a slow and incomplete response to an in vitro wound healing assay as well. The ability of FTls to affect these cellular abnormalitics was mixcd. Nuclear rigidity and wound-healing deficits were reversed in PTJ-treated proge ria cultures. However, FTI lreatment did not promote cell proIi ferat ion after mech an ical strai n.
Within the nucleus. lamin A monomers (jrst dimcrize, then dimcrs associate in a hcad-to-tail hlshion and Ilnally associate lateral Iy (23) . The 50-amino acid deletion in progerin probably does not affect its ability to c1imerize, as normallamin A does, because the necessary components for this function are not deleted. Hence progerin can form dimers with itself or nonnal lamin A, thereby influencing lamin A's interactions with nuclear pores, chromatin, and larnin binding partners. For example, the fOllllation of lamin A and lamin B arc separate yet interdependent; the failure of one lamin-type to properly form can interrere with the formation of another Iamin type (24) . Progerin build-up with increasing cell passage leads to progressively increased percentages or blebbed nuclei (25) . Roher! Goldman (Northwestern University) referred to these blebs as "sophisticated structures" worthy of close examination to detem1ine their intluence on cell Cunction, and began by hypothesizing that progerin's affect on other lamin types is central to the blebbing defect. In the region of the blebs, there is an absence of heterochromatin but euchromatin can be identified surrounded by lamin A. a configuration not observed in other regions where the nuclear membrane appears to be formed normally (26) . Dr. Goldman and his group suggest that the blebs contain transciptionally active DNA and that this is providing clues regarding the role of mutant larnin A in progeria.
Complementary chromosome positioning studies were explored by Joanna Bridger (BruneI University, U.K.), who supports the hypothesis that A-type lamins (and/or emerin) are involved in translocating and anchoring chromosomes to the nuclear membrane or nuclear matrix in nonrandom distributions according to cell cycle status, and that lamin mutations perturb this balance. Normally, upon cell cycle exit, gene-poor chromosomes move from the nuclear periphery to more interior positions (27, 28) . The distribution prollle of chromosome position within the nucleus during cell cycling, quiescence, and senescence all differ. Dr. Bridger had earlier reported that proliferating fibroblasts from laminopathy patients, including progeria, exhibited chromosome distributions characteristic of nonproliferating (senescent or quiescent) nO/lTIal fibroblasts, where the largest chromosomes are located at the periphery of the nucleus and the smallest at the interior. At the workshop, Dr. Bridger reported new experiments that distinguished the chromosome distribution in senescent from quiescent cells based on the position of chromosome 10, which she finds located at the periphery in quiescent cells and at the interior in senescent cells. In proliferating progeria Ilbroblasls, however, chromosome 10 was located at the periphery, a position round only in the nonprol iferating, quiescent state in n01111al cells. Several other proliferating laminopathy cultures also displayed the quiescent positioning. This chromosome positioning was not changed when progeria or laminopathy cells became senescent. The consequences of aberrant chromosome 10 locat ion on transcription in progeria will be the subject of Dr. Bridger's future studies.
Bryce Paschal (University or Virginia) reported on progerin-induced changes in the nuclear pore complexes (NPCs), channels through which all transport between the nucleus and the cytoplasm takes place (29) . He has found major changes both in NPC structure and in the transport machinery and signals. The structural change is in the position of the nucleoplasmic basket. a structure located at the pore on the nucleoplasmic side. It consists of two proteins: TPR (translocated promoter region), the key constituent, and Nup 153, a facilitator of its assembly. The entire basket structure is disassembled and reassembled at every mitosis. When Dr. Paschal looked for the localization or TPR in progeria fibroblasts by immunostaining, he obtained a striking result: Instead of being in the basket, TPR is out in the cytoplasm. The same result is obtained when human epithelial cells are lransfectcd with progerin. Administration of an FTJ to the culture corrected the TPR localization back into the nuclear envelope of progeria cells.
Progcrin also had a major effect on localization or a transport regulator. While small molecules can diffuse passively through the NPC channel, macromolecules must enter as a complex with a member of the superfamilies of importin or cxportin proteins, depending on the direction of transport (29) . Once one of these complexes has traversed the pore, it is dissociated with the involvement of a Ras related GTPase called RAN. In normal cells, there is a gradient of RAN concentration across the pore, with more RAN in the nucleus than in the cytoplasm.
Dr. Paschal found that the RAN protein gradient was disrupted in epithelial cells when lamin A was depleted with siRNA. He therefore examined the effect of several laminopathy mutations on RAN localization. Whereas cells from dilated cardiomyopathy and Emel),-Dreifuss muscular dystrophy mutations that express a mutant f01111 of lamin A had nonnal RAN gradients, the RAN protein gradient is dramatically disrupted in both progeria cells and in cells with the mutant Iamin A L647R in which cleavage by Zmpste24 is lacking. While in normal cells most of the RAN is in the nucleus, progeria cultures have an inverted gradient-there is more RAN in the cytoplasm than in the nucleus. In the L647R cultures, this effect was rescued by adding an fTf to the culture. It will be important to assess whether FTI rescues the RAN progerin gradient in progeria cells.
PROGERIA AND AGING
Hutchinson-Gilford progeria syndrome is named for its resemblance to aging: "pro" prematurely and "geras" aged. It is a segmental progeroid syndrome (30) , since some, but not all, of the patients' characteristics resemble accelerated aging. Over the last several years, a growing body of evidence for cellular and molecular overlaps between progeria and normal aging has been uncovered. Early investigations compared several properties, for example, telomere length (31) and distribution of mRNA species (32) . The discovel)' that progeria is caused by a mutation in lamin A, which had not previously been implicated in mechanisms of aging, brought in an entirely new question: Are defects in lamin A implicated in normal aging? The first positive evidence was reported by Scanldi and Misteli in 2006 (33), who showed thaI cell nuclei from nonnal individuals have acquired defects similar to progeria patients, including changes in histone modifications and increased DNA damage. Younger cells show considerably less of these defects. They further demonstrated that the age related effects are the result of the production of low levels of preprogerin mRNA produced by activation of the same cl)'ptic splice site that functions at much higher levels in progeria, and is reversed by inhibition of transcription at this splice site. Cao and colleagues (34) , studying the same phe nomenon, showed that, among interphase cells in fibroblast cultures, only a small fraction of the cells contained progerin.
The percentage of progerin-positive cells increased with passage number, suggesting a link to n0I111al aging. A large amount or the data presenled at this workshop underscored the value of studying progeria as a cellular and organismalmodel for some key aspects of the aging process. The evidence Ihat progerin is present in normal aging was considerably strengthened at the workshop by Karima Djahali (Columbia University) (35) . Dr. Djabali measured progerin mRNA and protein (using a monoclonal antibody she created that recognizes progerin but notlamin A) in cells from skin biopsies taken from progeria patients and from 150 n011nal participants with ages ranging from newborn to 97 years. Dr. Djabali found low levels of progerin mRNA in all tissue samples, but found progerin protein only in skin samples taken from elderly participants, within de11nal libroblasts, and in a few temlinally differentiated keratino cytes. Furthermore, using this same antibody, Dr. Djabali detected a dramatic increase of progerin-containing cells in nonnal dermal fibroblast cuHures as passage number increased. The discovery of progerin in the skin biopsies provided the first evidence for the in vivo accumulation of progerin during n01111al aging. The presence of progerin in n01111al individuals implies that individuals without progeria tolerate a low level of progerin as part of n01111al aging. With respect to treating progeria, it is encouraging and suggests that effective therapy may be achieved with a balance between prelamin, lamin A, and progerin rather than a complete elimination of the progerin molecule.
Francis Collins' latest research is asking a central question in the search for inlluences of LMNA or progerin production on longevity in the general population. Prompted by the Djabali evidence of increased amounts of progerin with age, Dr. Collins is looking for variations in DNA sequence around the LMNA gene in fibroblasts of' long-lived people that may give them a selective advantage over those individuals who die at younger ages. In an experiment that examined cells from more than lOon people aged greater than 94 years, he found that four single nucleotide polymorph isms (SNPs) differed from the general population (p 2 X 10""5). Four of four centenarians analyzed also contained these same SNPs. The probability of' this finding being random is 7 X IO-x . Further study will ask whether increases or decreases in progerin production are linked to these SNPs.
Nonnal cellular senescence is marked by increasing rates of DNA damage and a decline in the ability to repair this damage (36) . Progeria cells have been shown to accumulate double-stranded DNA (dsDNA) breaks and impaired DNA repair (37) (38) (39) . Yue Zou (East Tennessee State University) presented results on the mechanism of this failure (40) . Nonnally, in response to fOlmation of dsDNA breaks, histone H2AX is rapidly phosphorylated and then recruits various DNA repair proteins, together fonning foci for DNA repair. In progeria fibroblasts, the phosphOl)'lated protein, called gamma-H2AX, was unable to recruit the DNA repair enzymes Rad51 and Rad50. Instead, the damage recognition protein XPA (xeroden11a pigmentosum group A) was recruited. XPA nonnally participates only in excision repair systems and has no known role in dsDNA repair. Similar results were obtained from restrictive dermopathy cultures. Progerin also had a major effect on localization or a transport regulator. While small molecules can diffuse passively through the NPC channel, macromolecules must enter as a complex with a member of the superfamilies of importin or exportin proteins, depending on the direction of transport (29) . Once one of these complexes has traversed the pore, it is dissociated with the involvement of a Ras related GTPase called RAN, In normal cells, there is a gradient of RAN concentration across the pore, with more RAN in the nuclcus than in the cytoplasm.
Dr. Paschal found that thc RAN protein gradient was disrupted in epithelial cells when lamin A was depleted with siRNA. He therefore examined the effect of several laminopathy mutations on RAN localization. Whereas cells fi'om dilated cardiomyopathy and Emery-Dreifuss muscular dystrophy mutations that express a mutant 1'01111 of lamin A had nonnal RAN gradients, the RAN protein gradient is dramatically disrupted in both progeria cells and in cells with thc mutant lamin A L647R, in which cleavage by Zmpstc24 is lacking. While in normal cells most of the RAN is in the nucleus, progeria cultures have an invcrted gradient-there is more RAN in the cytoplasm than in the nucleus. In thc L647R cultures, Ihis effcct was rescued by adding an FTI to the culture. It will be important to assess whether FTI rescues the RAN progerin gradient in progeria cells.
Hutchinson-Gilford progeria syndrome is named for its resemblance to aging: "pro" = = prematurely and "gcras" = aged. It is a segmental progeroid syndrome (30) , since some, but not all, of the patients' characteristics resemble accelerated aging. Over the last several years, a growing body of evidence for cellular and molecular overlaps between progeria and normal aging has been uncovcred. Early investigations compared several properties, for example, telomere length (31) and distribution of mRNA species (32) . The discovery that progeria is caused by a mutation in lamin A, which had not previously been implicated in mechanisms of aging, brought in an entirely new question: Are defects in lamin A implicated in normal aging? The IIrsl positive evidence was reported by Scamdi and Misteli in 2006 (33) . who showed thai cell nuclei from nOllnal individuals have acquired defects similar to progeria patients, including changes in histonc modifications and increased DNA damage. Younger cells show considerably less of these defects. They further demonstrated that the age related effects are the resull of the production of low levels of preprogerin mRNA produced by activation of the same cryptic splice site that functions at much higher levels in progeria, and is reversed by inhibition of transcription at this splice site. Cao and colleagues (34) , studying the samc phe nomenon, showed that, among interphase cells in ll11roblast cultures, only a small fraction of the cells contained progerin.
The percentage of progerin-positive cells increased with passage number, suggesting a link to n0ll11al aging.
A large amount of the data presented at this workshop underscored the value of studying progeria as a cellular and organismalmodel for some key aspects of the aging process. The evidence that progerin is present in normal aging was considerably strengthened at the workshop by Kari117a Djahali (Columbia University) (35) . Dr. Djabali measured progerin mRNA and protein (using a monoclonal antibody shc created that recognizes progerin but not lamin A) in cells from skin biopsies taken from progeria patients and from 150 nonnal participants with ages ranging from newborn to 97 ycars. Dr. Djabali found low levels of progerin mRNA in all tissue samples. but found progerin protein only in skin samples taken from elderly participants, within dennal libroblasts, and in a few telminaJly differentiated keratino cytes. Furthermore, using this same antibody, Dr. Djabali detected a dramatic increase of progerin-containing cells in nonnal dermal fibroblast cullures as passage number increased. The discovery of progerin in the skin biopsies provided the first evidence for the in vivo accumulation of progerin during nonnal aging. The presence of progerin in nonnal individuals implies that individuals without progeria tolerate a low level of progerin as part of nonnal aging. With respect to treating progeria, it is encouraging and suggests that effective therapy may be achieved with a balance between prelamin. lamin A. and progerin rather than a complete elimination of the progerin molecule.
Francis Collins' latcst research is asking a central question in the search for influences of LMNA or progerin production on longevity in the general population. Prompted by the Djabali evidence of increased amounts of progerin with age, Dr. Collins is looking for variations in DNA sequence around the LMNA gene in libroblasts of long-lived people that may give them a selective advantage over those individuals who die at younger ages. In an experiment that examined cells from more than 1000 people aged greater than 94 years, he found thai four single nucleotide polymorph isms (SNPs) differed from the gcneral population (p = = 2 X 10")). Four of four centenarians analyzed also contained these same SNPs. The probability of this finding being random is 7 X la-x. Further study will ask whether increases or decreases in progerin production are linked to these SNPs. Nonnal cellular senescence is marked by increasing rates of DNA damage and a declinc in the ability 10 repair this damage (36) . Progeria cells have been shown to accumulate double-stranded DNA (dsDNA) breaks and impaired DNA repair (37) (38) (39) . Yu(' Zou (East Tennessee Slate University) presented results on the mechanism of this failurc (40) . Nonnally. in responsc to fOlmation of dsDNA breaks, histone H2AX is rapidly phosphorylated and then recruits various DNA repair proteins, logether fonning foci for DNA repair. In progeria libroblasts, the phosphorylated protein, called gamma-H2AX, was unable to recruit the DNA repair enzymes Rad51 and Rad50. Instead. the damage recognition protein XPA (xerodcnna pigmentosum group A) was recruited. XPA 110nnally participates only in excision repair systems and has no known role in dsDNA repair. Similar results were obtained from restrictive dermopathy cultures. 
HIGH-THROUGHPUT SCREENING SYSTEIVI

Stem Cells
For several presenting researchers, stem cells took center stage for two reasons. First, there is the question of whether or not progeria is a disease characterized by stem-cell depletion. whereby there is an inadequate supply or stem cells for replenishing prematurely dying mesenchyme derived cell populations (VSCM, adipocytes, llbroblasts, and osteocytes). Second, the lack of lamin A expression in immature cells presents stem-cell therapy as a viable strategy for treatment, or even reversal, of disease in progeria. The therapeutic potential of mesenchymal stem cells is being tested in numerous clinical and preclinical trials (42) .
In his introductory presentation, Huber Warner (Univer sity or Minnesota) advanced his hypothesis that depletion of stem cells is a major hlCtor in causing the tissue changes observed in progeria (43) . The depletion may arise from the increased turnover of differentiated cells, which are lost at an accelerated rate (44) . This hypothesis has been further analyzed in the literature. Prolla (45) suggested that the regenerative capacity of tissues with high turnover might be reduced due to the exhaustion or progenitor cells. Mesenchymal stem cells are believed to be involved in expression of symptoms of progeria, since most mesenchy mal stem cells express lamins A/C (46) , while some committed hematopoietic cell lines do not (47) . Gotzmann and Foisner (48) point out that deregulated or impaired tissue regulation and deregulated cell-type plasticity might account for nearly all pathological conditions detected in laminopathies. lIalaschek-Wiener and Brooks-Wilson (49) argue that depletion of mesenchymal stem cells can help account for the specific segmental nature of progeria. The current published literature supports the view that lamin A, and hence progerin, is produced by differentiated cells, and undiiTerentiated cells do not transcribe or translate either molecule. However, Carlos Lopez-Orin (Universidad de Oviedo, Spain) described experiment.s in which hair follicle-derived stem cells are severely affected by defects in the lamin processing pathway. His Zmpste24~1" progeria mouse model (50) produces no mature lamin A and suffers from a build-up of famesylated prelamin A. The homozy gous null mouse displays many features of human laminopathies, including severe growth retardation and premature death, dilated cardiomyopathy (DCM), muscular dystrophy (EDMD). lipodystrophy (progeria), and loss of fur and whiskers. Dr. Lopez-Otin's preliminary studies show that, unlike their wild-type counterparts, lllany hair follicle-derived stem cells from these mice were quiescent, showed profound nuclear blebbing, and the accumulation of heterochromatin in two large masses in the centers of many cell nuclei. In addition, clonogenic assays showed that these stem cells have a profound proliJ'eration defect abnOllllal accumulation of p16, and an absence of beta-catenin. suggesting a loss of wnl signaling. Imp011antly. when an LMNA allele was crossed into Zmpste24-1 mice, levels of famesylated prelamin A decreased, lamin A was synthesized, and all measured cellular defects were normalized (39) . Hence, in this system, stem-cell function was profoundly affected by nuclear defects and the ratio of farnesylated prclamin A to mature lamin A.
In light of this interest in the possibility that stem-cell depletion causes many of progeria's phenotypes, Irina Conboy (University of California at Berkeley) was invited to present her work on mechanisms causing the decline of tissue regenerative potential in normal aging skeletal muscle in response to injury and on regeneration using embryonic stem cells. She demonstrated both that a youthful bio chemical milieu can restore cell vitality, and that old cells have regenerative capacity that can be tapped.
Skeletal muscle has its own source of stem cells, called satellite cells. Satellite cells are located at the basement membrane of terminally di/Terentiated muscle fibers and can be identified and purified. Dr. Conboy has carried out both in vivo and in vitro experiments in which stem cells from young animals were exposed to niche clements from old animals and vice versa (51) . She has discovered that the decline of regenerative capacity with age results from changes in the stem cell niche, not in the stem cells themselves. A key element is age-related impairment of the up-regulation of the Notch ligand Delta after muscle injury (52) . Exposure of satellite cells from old mice to young serum enhanced the expression or Notch ligand Delta as well as proliferation and regenerative capacity of aged satellite cells. Forced activation of Notch by adding a Notch-speciflc antibody restored regenerative potential to old muscle.
Dr. Conboy has extended her studies to examine the eflects of aged systemic mileu on the runction of human embryonic stem cells (hESCs) (53) . Aged mouse serum dramatically inhibited the self-renewal and proliferative potential of hESCs and satellite cells, as measured by expression of markers of stem-cell functionality, rate of cell proliferation, and the capacity for myogenic differentiation. When hESCs are cultured in serum-free medium instead of immediate transJCr to medium containing aged serum, the cells are no longer susceptible to the effects of aged serum. This implies that hESCs have produced one or more anti aging factors.
Together, these experiments suggest that the regenerative outcome of stem-cell replacement will be determined by a balance between negative effects of aged tissues on transplanted cells and positive effects of embryonic cells on the endogenous regenerative capacity. This result indicates that a complex interplay between negative regulation by the 
For several presenting researchers, stem cells took cenler stage for two reasons. First, there is the question of whether or not progeria is a disease characterized by stem-cell depletion, whcreby there is an inadequate supply of stem cells for replenishing prematurely dying mesenchyme derived cell populations (VSCM, adipocytes, llbroblasts, and osteocytes). Second, the lack of lam in A expression in immature cells presents stem-cell therapy as a viable strategy lor treatment. or even reversal, of disease in progeria. The therapeutic potential of mesenchymal stem cells is being tested in numerous clinical and preclinical trials (42) .
In his introductory presentation, Huber Warner (Univer sity of Minnesota) advanced his hypothesis that depletion of stem cells is a major factor in causing the tissue changes observed in progeria (43) . The depletion may arise from the increased turnover of differentiated cells, which are lost at an accelerated rate (44) . This hypothesis has been further analyzed in the literature. Prolla (45) suggested lhat the regenerative capacity of tissues with high turnover might be reduced due to the exhaustion of progenitor cells. Mesenchymal stem cells are believed to be involved in expression of symptoms of progeria. since most mesenchy mal stem cells express lamins AIC (46) , while some committed hematopoietic cell lines do not (47) . Gotzmann and Foisner (48) point out lhat deregulated or impaired tissue regulation and deregulated cell-type plasticity might account for nearly all pathological conditions detected in laminopathies. IIalaschek-Wiener and Brooks-Wilson (49) argue that depletion of mesenchymal stem cells can help account for the speciflc segmental nature of progeria.
The current published literature supports the view that lamin A, and hence progerin, is produced by differentiated cells, and undifTerentiated cells do not transcribe or translate either molecule. However, Carlos Lopez-Orin (Universidad de Oviedo, Spain) described experiments in which hair fall ide-derived stem cells are severely affected by defects in the Jamin processing pathway. His Zmpste24-1 · progeria mouse model (50) produces no mature lamin A and suffers from a build-up of famesylated prelamin A. The homozy gous null mouse displays many features of human laminopathies, including severe growth retardation and premature death, dilated cardiomyopathy (DCM), muscular dystrophy (EDMD). lipodystrophy (progeria), and loss of fur and wh iskers. Dr. Lopez-OLin's pre Ii mi nary studies show that, unlike their wild-type counterparts. many hair follicle-derived stem cells li'OIn these mice were quiescent, showed profound nuclear blebbing, and the accumulation of heterochromatin in lwo large masses in the centers of many cell nuclei. In addition, clonogenic assays showed that these stem cells have a profound prolilCration defect. abnollllal accumulation of p 16, and an absence or beta-catcnin, suggesting a loss or wnl signaling. ImpOliantly, when an LMNA allele was crossed into Zmpste24-1 --mice. levels of famesylated preJamin A decreased. lamin A was synthesized, and all measured cellular defects were normalized (39) . Hence, in this system, stem-cell function was profoundly affected by nuclear defects and the ratio or farnesylated prelamin A to mature lamin A. In light of this interest in the possibility that stem-cell depletion causes many of progeria's phenotypes. Irina Conboy (University of California at Berkeley) was invited to present her work on mechanisms causing the decline of tissue regenerative potential in normal aging skeletal muscle in response to injury and on regeneration using embryonic stem cells, She demonstrated both that a youthful bio chemical milieu can restore cell vitality, and that old cells have regenerative capacity that can be tapped.
Skeletal muscle has its own source of stem cells, called satellite cells. Satellite cells are located at the basement membrane of terminally dilTerentiated muscle fibers and can be identified and purified. Dr. Con boy has carried out both in vivo and in vitro experiments in which stem cells Ii'om young animals were exposed to niche clements from old animals and vice versa (51) . She has discovered that the decline of regenerative capacity with age results li'om changes in the stem cell niche, not in the stem cells themselves, A key element is age-related impairment of the up-regulation of the Notch ligand Delta after muscle injury (52) . Exposure of satellite cells from old mice to young serum enhanced the expression or Notch ligand Delta as well as proliferation and regenerative capacity of aged satellite cells. Forced activation of Notch by adding a Notch-speciflc antibody restored regenerative potential to old muscle.
Dr. Conboy has extended her studies to examine the eflccts of aged systemic mileu on the function of human embryonic stem cells (hESCs) (53) . Aged mouse serum dramatically inhibited the self-renewal and proliferative potential of hESCs and satellite cells, as measured by expression of markers of stem-cell functionality, rate of cell proliferation, and the capacity for myogenic differentiation. When hESCs are cultured in serum-free mcdium instead of immediate transfer to medium containing aged serum, the cells are no longer susceptible to the effects of aged scrum. This implies that hESCs have produced one or more anti aging factors.
Together. these experiments suggest that the regenerative outcome of stem-cell replacement will be determined by a balance between negative effects of aged tissues on transplanted cells and positive effects of embryonic cells on the endogenous regenerative capacity. This result indicates that a complex interplay between negative regulation by the aged niche and positive regulation by hEses will likely determine the success of hESe-based cell replacement therapies. Dr. Conboy's observations in striated muscle pro vide a well-tested pathway for studying the key questions or the role of stem cells and aging in progeria, and arc easily adaptable to the progeria mouse model. Tom M;steli and Paola 5;cqlfidi (National Cancer In stitute) presented the lirst evidence supporting the hypoth esis that stem-cell depletion is a factor in organismal symptoms or progeria (53) . The first stcp of their approach was to determine what gene expression programs are affected by progcrin. The experimental system consisted of an imm0l1alized skin fibroblast cell line that expresses inducible green fluorescent protein (GFP) progerin. In this system, signiJkant progerin accumulation was flrst observed 5 days after induction and reached a plateau after 10 days at levels similar to those found in cells rrom progeria patients. This system allowed analysis of time-dependent changes in transcriptional proilies in response to progerin expression and compared to expression of GFP-tagged wild-type lamin A as a control.
Among genes known to influence differentiation, pro gerin induction led to up-regulation of several genes in the Notch signaling pathway, most prominently Hes I, Hes 5, and Hey I. This up-regulation was also found in progeria cells. Consistent with a direct role of nuclear progerin in their regulation, these genes are all in the downstream portion of the Notch pathway, and no increase was found in cleaved Notch expression or in the upstream cleavage reaction. This result dovetailed with Dr. Conboy's observa tions that Notch is important for maintenance of stem cells (including mesenchymal stem cells) and differentiation pathways, and points to the Notch pathway as a key element in progeria.
Drs. Misteli and Scarndi fUliher explored the effects of progerin on differentiation by inducing stem cells to go down various differentiation pathways (54) . Preliminary results showed that the rate of osteogenesis was increased, adipo genesis was blocked, and chondrogenesis was not affected. They hypothesize that progeria leads to the activation of part of the Notch pathway that causes differentiation, and that accelerated aging in progeria patients is largely the result or stem-cell dysfunction.
ALTERNATIVE PI{ENVLATION AND THE NEED FOR COMBJNATION CHEMOTHEUAPV IN PROGERIA
Posttranslational processing to create lamin A involves several fon11s of prelamin A, both farnesylated and unfarnesylated (Figure 1) . FYI treatment presumably leads to unusually increased cellular levels of nonfarnesylated f0I111s of prelamin A and progerin, and could theoretically promote alternative prenylation (geranylgeranylation). The influences of nonfarnesylated prelamin A and progerin on cell function and disease status have yet to be intensely explored. Michael Sinensky (East Tennessee State Univer sity) has begun to examine alternative prenylation (ger anylgeranylation) of preJamin A and progerin under the influence of FYI. He finds thaI, in cells treated with an FTI, several important cellular events occur: First, geranylgeranyl is incorporated into prelamin 10 yield a geranylgeranylated intermediate. He also finds that Zmpste24 does cleave both famesylated and gcranylgeranylated prelamin A, and therefore mature lamin A is produced even in the complete absence of farnesylation. However, he finds that the farnesylated prelamin A is a 20-fold beHer substrate than geranylgeranylated prelamin A. Therefore, processing of geranylgeranylated prelamin A is slow, resulting in abnormal accumulation of nonfarnesylated prelamin A within cells. Progerin also became geranylgeranylated in cells treated with FTI, creating a new prenylated protein.
Prelamin A accumulation can afrect cell cycling (55) . There is a paucity or data available comparing the behavior of geranylgeranylated versus farnesylated prelamin A or progerin, and this area of research may be essential to designing Future treatments for progeria since altemative prenylation can alter the behavior and function of cells (56) .
In a set of experiments with tremendous breadth, Car/os Lopez-Otin examined the potential role of lamin intennedi ates in disease, round support for alternative prenylation of prelamin A, and effectively treated a progeria mouse model using combination chemotherapy that intenupts progerin production at multiple points (57) . The effects of lamin intetmediates were first addressed. Dr. Lopez-Olin created a "triple mutant" mouse model lhat has the complete absence of both the Zmpste endonuclease and farnesyl transferase postnatally and is therefore the genetic equiva lent of complete famesyltransferase inhibition. I-Ience, only nonfarnesylated prelamin A is created in this mouse after bilih. Strikingly, the phenotype of these mice mimicked the Zmpste24-1 ---only mice, without phenotype rescue. Dr. Lopez-Olin hypothesized that the phenotype was caused either by the accumulation of nonfarnesylated prelamin A, or by an alternatively prenylaled prelamin A product. To resolve this issue, he tumed to cell culture, and cletell11ined which species of prelamins were present in Zmpste24-1 cells with and without FTI treatment. As expected. famesylated prelamin A was present in Zmpste24-1 cell extracts. However, when FYI was added to Zmpste24-1-cell cultures, the amount of famesylated prelamin A decreased, and geranylgeranylated prelamin A appeared. By extrapo lation from FTI treated Zmpste24-1 cultured cells to triple mutant mice, he h~~?thesized that the absence or farnesy lation in Zmpste24 mice does not improve the phenotype in vivo because geranylgeranylated prelamin A is created, and this product may be al least partly responsible for disease phenotype in the triple mutant mice.
Dr. Lopez-Otin went on to treat Zmpste24-1 mice with two commercially available drugs, statins and bisphospho nates. These drugs block two diFferent steps in the mevalonate pathway, upstream from blrnesyltransferase and geranylgeranyltransferase (Figure 2) . Treatment of Zmpste24-F mice with statins and hisphosphonales in creased their 20-week life span by 80%. There was also impressive rescue of bone phenotypes, and cellular blebbing was substantially reducecl. FU11her research is needed to understand the mechanism responsible for extended life span in treated mice, since bisphosphonates home specifi cally to bone. However, Dr. Lopez-Otin presents us with the Ilrst preliminary evidence that combination chemotherapy aged niche and posItive regulation by hESCs will likely determine the success of hESC-based cell replacement therapies. Dr. Conboy's observations in striated muscle pro vide a well-tested pathway for studying the key questions or the role of stem cells and aging in progeria, and are easily adaptable to the progeria mouse model.
Tom Misteli and Paala SNdfidi (National Cancer In stitute) presented the first evidence supporting the hypoth esis that stem-cell depletion is a ractor in organismal symptoms of progeria (53) . The first step of their approach was to determine what gene expression programs are affected by progerin. The experimental system consisted of an imm0l1alized skin fibroblast cell line that expresses inducible green fluorescent protein (GFP) progerin. In this system, signiJkant progerin accumulation was (Jrst observed 5 days after induction and reached a plateau after 10 days at levels similar to those found in cells from progeria patients. 111is system allowed analysis of time-dependent changes in transcriptional proflles in response to progerin expression and compared to expression of GFP-tagged wild-type lamin A as a control.
Among genes known to influence differentiation, pro gerin induction led to up-regulation of several genes in the Notch signaling pathway, most prominently Hes I. He... 5.
and Hey I. This up-regulation was also found in progeria cells. Consistent with a direct role of nuclear progerin in their regulation, these genes are all in the downstream portion of the Notch pathway, and no increase was found in cleaved Notch expression or in the upslream cleavage reaction. This result dovetailed with Dr. Conboy's observa tions that Notch is imporlant for maintenance of stem cells (including mesenchymal stem cells) and differentiation pathways, and points to the Notch pathway as a key elemenl in progeria.
Drs. Misteli and Scaffidi fUl1hcr explored the effects of progerin on differentiation by inducing stem cells to go down various differentiation pathways (54) . Preliminary results showed that the rate of osteogenesis was increased, adipo genesis was blocked, and chondrogenesis was not affected. They hypothesize that progeria leads to the activation of part of the Notch pathway that causes differentiation. and that accelerated aging in progeria patients is largely the result of stem-cell dysfunction.
ALTERNATIVE PRENVLATION AND THE NEED FOI~
COMnJNATION CHEMOTHEUAPV IN PROGERIA
Posttranslational processing to create lamin A involves several fonns of prelamin A, both farnesylated and unfarnesylated (Figure 1) . FYI treatment presumably leads to unusually increased cellular levels of nonl~lrnesylated for111s of prelamin A and progerin, and could theoretically promote alternative prenylation (geranylgeranylation). (55) . There is a paucity of data available comparing the behavior of geranylgeranylated versus farnesylated prelamin A or progerin, and this area of research may be essential to designing future treatments for progeria since altemative prenylation can alter the behavior and function of cells (56) .
In a set of experiments with tremendous breadth, Carlos Lope::.-OtiJl examined the potential role of lamin intennedi ates in disease, found support for alternative prenylation of prelamin A. and effectively treated a progeria mouse model using combination chemotherapy that inten-upts progerin production at multiple points (57) . The effects of lamin intelmediates were first addressed. Dr. Lopez-Otin created a "triple mutant" mouse model that has the complete absence of both the Zmpste endonuclease and farnesyl transferase postnatally and is therefore the genetic equiva lent of complete famesyltransferase inhibition. Hence, only nonfarnesylated prelamin A is created in this mouse after bil1h. Strikingly, the phenotype of these mice mimicked the Zmpste24-1 ---only mice, without phenotype rescue. Dr. Lopez-Otin hypothesized that the phenotype was caused either by the accumulation of nonfarnesylated prelamin A. or by an alternatively prcnylated prelamin A product. To resolve this issue, he fumed to cell culture, and cletemlined which species of prelamins were present in Zmpste24-1 cells with and withollt FTI treatment. As expected. famesylated prelamin A was presenl in Zmpste24-1 --cell extracts. However, when FYI was added to Zmpste24-1-cell cultures, the amount of farnesylated prelamin A decreased, and geranylgeranylated prelamin A appeared. By extrapo lation from FTI treated Zmpste24-1 --cultured cells 1.0 triple mutant mice, he hy~othesized Ihat Ihe absence of l'arnesy lation in Zmpste24 ' " --, -, mice does not improve the phenotype in vivo because geranylgeranylated prelamin A is created. and this product may be at least partly responsible for disease phenotype in the triple mutant mice.
Dr. Lopez-Otin went on to treat Zmpste24-1 --mice with two commercially available drugs, stalins and hisphospho nates. These drugs block two different steps in the mevalonate pathway, upstream from f~lrnesyltranslerase and geranylgeranyltransferase (Figure 2) . Treatment of Zmpste24-F -mice with statins and hisphosphonates in creased their 20-week life span by 80%. There was also impressive rescue of bone phenotypes, and cellular blebbing was substantially reduced. FU11her research is needed to understand lhe mechanism responsible for extended Ii fe span in treated mice, since hisphosphonates home specifi cally to bone. However, Dr. Lopez-Otin presents us with the first preliminary evidence that combination chemotherapy vicinity of the LMNII gene, a step toward identifying LMNA genotypes involved in longevity. Links between progerin, progeria, and the cardiovascular disease in aging are still in their early stages, as most experiments have been conducted on flbroblast cultures and should be extended to vascular cell types in future studies. However, pathological and clinical studies in humans and mice point to a nonlipid driven vascular stitTening shared by both progeria patients and elderly individuals.
As the current drug trial for progeria is testing an FTI, there was much focus on the biological mechanisms that involve farnesylation during posttransJational steps that lead to lamin A. In a progeria model mouse, the first evidence was presented that FYI may reverse the damaging effects of progeria in vivo, even when administered after vascular damage has occurred. The importance of this result becomes obvious when one recalls that progeria is not diagnosed until significant damage to organ systems has taken place. In the numerous basic science studies on cellular effects in pro geria, investigators onen checked whether FTI treatment affected the cellular damage under study. As shown in Table I , some but not all were reversed by FTI treatment Drug discovery is an important direction to pursue in progeria. especially in light of the possibility that drugs thai help these children may also be beneficial to the !lonnal aging population and a large fraction of men and women afflicted with cardiovascular disease. High-throughput screening (HTS) is an essential first step in drug de velopment. The key 10 HTS is to develop an assay that easily detccts some visible change in the target cells, due to exposure to a chemical compound that can be quickly and reliably read by a sensor. Nuclear blebbing has been used to measure improvement in progeria cells in response to various drugs such as FYIs. However, for testing chemical libraries on a large scale, such morphological assays are unsuitable. Tom Misteli and CordeJle Tanega (National Cancer Institute) have developed what could be a break through testing strategy. The Misteli laboratory has pre viously showed that blocking the cryptic splice site that is activated by the progeria mutation with a complementary oligonucleotide restores the phenotype of progeria hbro blasts to normalcy (58) . Because satishlctory methods for system-wide introduction of oligonucleotides to humans do not yet exist, Misteli has embarked on a search for small molecules that specifically inhibit the altemate spicing created in exon 11. The work is being carried out at a fully automated high-throughput system for drug screening at the NIH Chemical Genome Center.
Dr. Misteli devised a system based on dual fluorescence reporters that indicates whether the cl)'ptic splice site in LMNA is used or not. After development, the assay was characterized using the available oligonucleotide and optimized for HTS. In pilot experiments, a small library of 1279 compounds was tested at seven concentrations, thereby producing a titration curve on the first screen. A large screen of 150,000 compounds followed, and led to the identification of 100 compounds based on their response profiles as well as structural and phannacological considerations. Experiments are now under way to test these compounds in progeria fibroblasts, looking at cell pheno types, splicing activity, and specilkity.
DISCUSSION
The presentations, posters, and discussion at the 2007 Progeria Workshop showed extraordinary progress at all levels-from basic science, mouse and human studies that beller define the biological effects of progerin on disease pathogenesis and on aging and cardiovascular disease in the general population., to the first clinical drug trial for progeria. The discovery that progerin is found in normal human fibroblasts in an age-dependent manner establishes a new link between progeria and aging. This is the best example yet of how studies on progeria may be valuable to understanding human aging. In addition, preliminary studies on samples from people over the age of 94 years found distinguishing single-nucleotide polymorph isms in the using FTI along with drugs that affect both progerin production and alternative prenylation could be efficacious. 785 
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using FTI along with drugs Ihal affect both progerin production and alternative prenylation could be efficaciolls.
A POWERFlJL NEW TESTING STI~ATEGY FOR DRUG DISCOVERY IN PROGERIA Drug discovery is an important direction to pursue in progeria. especially in light of the possibility that drugs thai help these children may also be benetlcial to the nonnal aging population and a large fraction of men and women afflicted with cardiovascular disease. High-throughput screening (HTS) is an essential first step in drug de velopmcnt. The key to HTS is to develop an assay that easily detects some visible change in the target cells, due to exposure to a chemical compound that can be quickly and reliably read by a sensor. Nuclear blebbing has been used to measure improvement in progeria cells in response to various drugs such as FTIs. However, for testing chemical libraries on a large scale, such morphological assays are unsuitable. Tom Misteli and CordeJle Tanega (National Cancer Institute) have developed what could be a break through testing strategy. The Misteli laboratory has pre viously showed that blocking the cryptic splice site that is activated by the progeria mutation with a complementary oligonucleotide restores the phenotype of progeria fibro blasts to normalcy (58) . Because satisl~lctory methods for system-wide introduction of oligonucleotides to humans do not yet exist. Misteli has embarked on a search for small molecules that specifically inhibit the altemate spicing created in exon 1 I. The work is being carried out at a fully automated high-throughput system for drug screening at the NIH Chemica] Genome Center.
Dr. Misteli devised a system based on dual fluorescence reporten; that indicates whether the cryptic splice site in LMNA is used or not. After development, the assay was characterized using the available oligonucleotide and optimized for HTS. In pilot experiments, a small library of 1279 compounds was tcsted al seven concentrations, thereby producing a titration curve on the first screen. A large screen of ~ 150.000 compounds followed, and led to the identification Qf ~ 100 compounds based on their response proflles as well as structural and phannacological considerations. Experiments are now under way to test these compounds in progeria fibroblasts, looking at cell pheno types, splicing activity, and specilkity.
DISCUSSION
The presentations, posters, and discussion at the 2007 Progeria Workshop showed extraordinary progress at all levels-from basic science, mouse and human studies that better define the biological effects of progerin on disease pathogenesis and on aging and cardiovascular disease in the general population, to the first clinical drug trial for progeria. The discovery thal progerin is found in normal human fibroblasts in an age-dependent manner establishes a new link between progeria and aging. This is the best example yet of how studies on progeria may be valuable to understanding human aging. In addition, preliminary studies on samples from people over the age of 94 years found distinguishing single-nucleotide polymorphisl11s in the IReproduced by permission of the puhlisher.] vicinity of the LMNIl. gene, a step toward identifying LMNA genotypes involved in longevity. Links between progerin, progcria, and the cardiovascular disease in aging are still in their early stages. as most experimcnts have been conducted 011 Ilbroblast cultures and should be cxtended to vascular cell types in future studies. However, pathological and clinical studies in humans and mice point to a nonlipid driven vascular stiffening shared by both progeria paticnts and elderly individuals.
As the current drug trial for progeria is testing an FTL there was much focus on the biological mechanisms that involve farnesylation during posttranslational steps that lead to lamin A. In a progeria model mouse, the first evidence was presented that FTT may reverse the damaging effects of progeria in vivo, even when administered after vascular damage has occurred. The importance of this result becomes obvious when one recalls that progeria is not diagnosed until significant damage to organ systems has taken place. In the numerous basic science studies on cellular effects in pro geria, investigators onen checked whether FTJ treatment affected the cellular damage under study. As shown in Table I , some but not all were reversed by FTI treatment.
Whether this will translate into some, but not complete, clinical improvement with FTI remains to be determined.
Pivotal j~lCtorS for disease phenotype that emerged during this workshop included the balance between multiple prclamin A [011115, mature lamin A, and progerin, the presence of alternative prenylation. and epigenetic changes modifying chromatin structure. It is highly likely that, as with most diseases, improving quality and longevity of life for children with pro gena will reqUire intense and multi pronged research. The emerging data hold promise that progeria may be amenable to single or combination chemotherapy, stem-cell therapy. and genetic therapies. In addition. this fleld or study has already brought an entirely new gene (LMNA) and its protein products (lamin A and progerin) into the aging and cardiovascular l1eJds. Future research should concentrate 011 understanding the influences of balancing prelamin A, lamin A, and progerin not only in progeria, but on health and longevity in all of us.
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